In Brief: Haemonetics' John White
This article was originally published in The Gray Sheet
Haemonetics' John White: Chairman and CEO steps down Jan. 27 at the request of the board of directors, which cites a leveling off in the blood products and processing systems maker's financial performance over the last two years. White is succeeded as CEO by James Peterson, formerly vice chairman and president of Haemonetics International. Succeeding White as chairman is Sir Stuart Burgess, who has been a board member since 1992 and is former CEO of Amersham International. White, who had been CEO since 1985, "helped to grow the company from a $32 mil. business to a global firm with over $300 mil. in revenues," the firm notes. For the three months ended Dec. 27, net revenues decreased 1% to $75.8 mil. Excluding the effect of a $25.2 mil. restructuring charge, net income declined 33% to $4.7 mil...
You may also be interested in...
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.